184 related articles for article (PubMed ID: 32616400)
1. A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer.
Gill J; Cetnar JP; Prasad V
Trends Cancer; 2020 Sep; 6(9):736-738. PubMed ID: 32616400
[TBL] [Abstract][Full Text] [Related]
2. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States.
Zaim R; Redekop K; Uyl-de Groot CA
J Cancer Policy; 2022 Sep; 33():100346. PubMed ID: 35779788
[TBL] [Abstract][Full Text] [Related]
4. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.
Ribeiro TB; Buss L; Wayant C; Nobre MRC
PLoS One; 2020; 15(7):e0236345. PubMed ID: 32706800
[TBL] [Abstract][Full Text] [Related]
5. Lurbinectedin: First Approval.
Markham A
Drugs; 2020 Sep; 80(13):1345-1353. PubMed ID: 32816202
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration.
Liang F; Zhang S; Wang Q; Li W
BMC Cancer; 2020 Aug; 20(1):823. PubMed ID: 32867707
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors in Small Cell Lung Cancer: Is It Also a Matter of Helios- Cells?
Mormile R
Pathol Oncol Res; 2020 Apr; 26(2):1355-1356. PubMed ID: 30927205
[No Abstract] [Full Text] [Related]
8. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
[TBL] [Abstract][Full Text] [Related]
9. The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.
Friedlaender A; Liu SV; Passaro A; Metro G; Banna G; Addeo A
Clin Lung Cancer; 2020 Nov; 21(6):e539-e543. PubMed ID: 32499210
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC).
Ma X; Wang S; Zhang Y; Wei H; Yu J
J Cancer Res Clin Oncol; 2021 Feb; 147(2):593-606. PubMed ID: 32852633
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.
Kubo T; Watanabe H; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Rai K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
Jpn J Clin Oncol; 2020 Dec; 50(12):1447-1453. PubMed ID: 32869100
[TBL] [Abstract][Full Text] [Related]
12. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC.
Walia A; Prasad V
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9513-9515. PubMed ID: 37178425
[TBL] [Abstract][Full Text] [Related]
14. Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular Carcinoma.
Gyawali B
J Natl Compr Canc Netw; 2019 Jun; 17(6):760-762. PubMed ID: 31200350
[No Abstract] [Full Text] [Related]
15. An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).
Sharp J; Prasad V
BMC Cancer; 2022 Jan; 22(1):70. PubMed ID: 35034621
[TBL] [Abstract][Full Text] [Related]
16. Assessing tumor-related signs and symptoms to support cancer drug approval.
Williams G; Pazdur R; Temple R
J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
[TBL] [Abstract][Full Text] [Related]
17. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.
Wilson BE; Desnoyers A; Nadler MB; Tibau A; Amir E
Cancer Med; 2021 Aug; 10(16):5405-5414. PubMed ID: 34323019
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies.
Rittberg R; Czaykowski P; Niraula S
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409254
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
Sherman S; Rotem O; Shochat T; Zer A; Moore A; Dudnik E
Lung Cancer; 2020 May; 143():40-46. PubMed ID: 32203769
[TBL] [Abstract][Full Text] [Related]
20. Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis.
Hudgins JD; Bacho MA; Olsen KL; Bourgeois FT
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):161-167. PubMed ID: 29148107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
